Deubiquitinating Enzyme A Biomarker for Endometrial Cancer Recurrence
By LabMedica International staff writers Posted on 31 May 2016 |

Image: A histologic view of an endometrial adenocarcinoma showing many abnormal nuclei (Photo courtesy of Wikimedia Commons).
Cancer researchers have found that expression of the deubiquitinating enzyme USP14 (Ubiquitin-specific protease 14) is elevated in endometrial adenocarcinoma and could serve as a biomarker to identify patients at risk for recurrence of the disease.
Most endometrial cancer cases are diagnosed at an early stage, and patients have a good chance of recovery. However, a subset of patients with early stage and low-grade disease experience recurrence for reasons that remains unclear. Recurrence is often accompanied by chemoresistance and high mortality.
Investigators at the University of Minnesota (Minneapolis, USA) have found that the chemoresistance may be linked to the expression of the deubiquitinating enzyme (DUB) USP14. DUBs are key components of the ubiquitin-dependent protein degradation pathway and act as master regulators in a number of metabolic processes including cell growth, differentiation, and apoptosis. They have been shown to be upregulated in a number of human cancers, and their aberrant activity has been linked to cancer progression, initiation, and onset of chemoresistance.
The investigators found that USP14 was expressed along with the marker of proliferation Ki67 in endometrial cancer cells in situ. Furthermore, pharmacological targeting of USP14 with the [U.S.] Food and Drug Administration approved small-molecule inhibitor VLX1570, decreased cell viability in chemotherapy resistant endometrial cancer cells with a mechanism consistent with cell cycle arrest and caspase-3 mediated apoptosis.
"We have discovered that women with high levels of USP14 are seven time more likely to recur than women with low levels of it," said senior author Dr. Martina Bazzaro, assistant professor of obstetrics, gynecology and women's health at the University of Minnesota. "Knowing a patient's status with regards to USP14 positivity could make a tremendous difference in terms of how a patient is treated and ultimately save her life."
"Our next step is a clinical trial. Patients with low risk endometrial cancer will be given the diagnostic exam, utilizing USP14 to gauge the levels of the cancer," said Dr. Bazzaro. "Those with high amounts - a positive test - will be treated more aggressively than current treatments to help prevent potential recurrence. Knowing more about their individual cancers can help us as clinicians to tailor a care plan specifically for them."
The study was published in the April 18, 2016, online edition of the journal Oncotarget.
Related Links:
University of Minnesota
Most endometrial cancer cases are diagnosed at an early stage, and patients have a good chance of recovery. However, a subset of patients with early stage and low-grade disease experience recurrence for reasons that remains unclear. Recurrence is often accompanied by chemoresistance and high mortality.
Investigators at the University of Minnesota (Minneapolis, USA) have found that the chemoresistance may be linked to the expression of the deubiquitinating enzyme (DUB) USP14. DUBs are key components of the ubiquitin-dependent protein degradation pathway and act as master regulators in a number of metabolic processes including cell growth, differentiation, and apoptosis. They have been shown to be upregulated in a number of human cancers, and their aberrant activity has been linked to cancer progression, initiation, and onset of chemoresistance.
The investigators found that USP14 was expressed along with the marker of proliferation Ki67 in endometrial cancer cells in situ. Furthermore, pharmacological targeting of USP14 with the [U.S.] Food and Drug Administration approved small-molecule inhibitor VLX1570, decreased cell viability in chemotherapy resistant endometrial cancer cells with a mechanism consistent with cell cycle arrest and caspase-3 mediated apoptosis.
"We have discovered that women with high levels of USP14 are seven time more likely to recur than women with low levels of it," said senior author Dr. Martina Bazzaro, assistant professor of obstetrics, gynecology and women's health at the University of Minnesota. "Knowing a patient's status with regards to USP14 positivity could make a tremendous difference in terms of how a patient is treated and ultimately save her life."
"Our next step is a clinical trial. Patients with low risk endometrial cancer will be given the diagnostic exam, utilizing USP14 to gauge the levels of the cancer," said Dr. Bazzaro. "Those with high amounts - a positive test - will be treated more aggressively than current treatments to help prevent potential recurrence. Knowing more about their individual cancers can help us as clinicians to tailor a care plan specifically for them."
The study was published in the April 18, 2016, online edition of the journal Oncotarget.
Related Links:
University of Minnesota
Latest Pathology News
- Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
- New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
- AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Testing Blood Samples for Proteins Can Reveal Malaria Severity
Malaria is a life-threatening disease that can rapidly deteriorate a patient's condition, making it difficult to predict which individuals are at risk of severe outcomes. It remains a challenge to diagnose... Read more
Genetic Testing Benefits Critically Ill Adults
Genetic disorders are often underdiagnosed in adults, despite their significant role in causing critical illnesses, especially in intensive care units (ICUs). It has long been believed that the likelihood... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more